Facilitated By

San Antonio Medical Foundation

News

  • Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of ...

    ... drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that .... NERLYNX is a registered trademark of Puma Biotechnology, Inc.

  • Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 ...

    Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of ... HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio ...

  • Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS ...

    ... from the Phase 3 RECOVER clinical study was presented during the 2018 San Antonio Breast Cancer Symposium ® (SABCS). ... Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, ...

  • Recon: HHS Defends Drug Pricing Proposal; Mallinckrodt to Spin Off Specialty Generics Business

    Pharmaceuticals & Biotechnology ... Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium (Press); Puma Biotechnology Presents ...

  • Let's make Texas the 'third coast' for biotech

    Texas has made a name for itself in biotech by supporting premier ... In San Antonio, one of every six workers is employed in the city's flourishing ...